Please assess the completion status of the following clinical trial:

Trial Title: Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults 2-65 years of age (inclusive) of either gender.~* Diagnosis of VL confirmed by spleen or bone marrow aspirate.~* Clinical signs and symptoms compatible with VL.~* Biochemical and haematological test values as follows:~* Haemoglobin \> 3.5g/100mL~* White blood cell count \> 0.75 x109/L~* Platelet count \> 40 x 109/L~* AST, ALT and alkaline phosphatase \< 5 times upper normal limit~* Prothrombin time \< 4 seconds above control~* Serum creatinine levels - 1.5 times upper normal limit~* Serum potassium levels within normal limits~* HIV negative.~Exclusion Criteria:~* A history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or drug addiction; renal, hepatic, cardiovascular or CNS disease; diabetes; tuberculosis; other infectious or major psychiatric diseases) that may introduce variables that affect the outcome of the study.~* Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up.~* Proteinuria (\> 2+).~* A history of allergy or hypersensitivity to amphotericin B~* Previous treatment for VL within two weeks of enrollment into the study.~* Prior treatment failures with amphotericin B.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): a single dose of 10 mg/kg of liposomal amphotericin B
- 2 (Type: ACTIVE_COMPARATOR): amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).